Company / Total Debt
Regeneron Pharmaceuticals Total Debt History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$2.0B
FY2025
5-year range
$2.0B / $2.0B
FY2021-FY2025
Trend
+0.1%
vs FY2024
Sector context
#22 of 83
Health Care
What the data says
At $2.0B, Regeneron Pharmaceuticals's total debt ranks #62 of 83 in the Health Care sector. Total Debt has increased for 6 consecutive years, from $0 in FY2019 to $2.0B in FY2025.
Based on SEC 10-K filings.
$2.0B in FY2025 with a 5-year CAGR of +0.1%.
Remained stable around $2.0B over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- +0.1%
- 5-Year CAGR
- +0.1%
- 10-Year CAGR
- -
Sector benchmark
#62 of 83 in Health CareTop 73% of 83This company $2.0B Sector average $6.2B
▼
-67.7% below sector average
Key checks
Key Insights
- Regeneron Pharmaceuticals's total debt has grown for 5 consecutive years.
- 5-year CAGR of +0.1%, indicating consistent growth.
- In FY2025, total debt increased 0.1% year-over-year.
- Ranks #22 out of 83 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.0B | +0.1% |
| FY2024 | $2.0B | +0.1% |
| FY2023 | $2.0B | +0.1% |
| FY2022 | $2.0B | +0.1% |
| FY2021 | $2.0B | +0.1% |
| FY2020 | $2.0B | - |
| FY2019 | $0 | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026